Compare Hyatt Hotels Corporation (H) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs TG Therapeutics Inc — how do they compare? Hyatt Hotels Corporation trades at $161.78 (market cap $15.02B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Hyatt Hotels Corporation is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and TG Therapeutics Inc for 16 Days on average.
| H | TGTX | |
|---|---|---|
Market Cap | $15.02B | $8.16B |
Volume | 842,340 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $59.06 |
52-Week Low | $135.42 | $26.94 |
Typical Hold Time | 148 Days | 16 Days |
Enterprise Value | $18.93B | $8.37B |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $161.94, up 3.05% today, near its pivot point of $159 with resistance at $162. The stock shows mixed technical signals but has consistently beaten earnings estimates in recent quarters. Revenue grew to $7.10B in 2025, though net income was negative. Analyst consensus is a Moderate Buy with a $197.77 price target, supported by recent strategic collaborations like the Delta Air Lines loyalty partnership announced September 9, 2026.
The outlook is cautiously optimistic given strong fee growth and expansion plans, but high valuation (P/E 196.83) and debt levels pose risks. Earnings momentum from Q3 2026 results, due October 29, 2026, will be critical for sustaining upside. Investors face volatility from regional economic weakness and project delays, requiring patience despite long-term growth targets.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
